Showing results (161-170 of 605) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|January 23, 2021
The Healthcare Cost Burden in Adults with High Risk for Cardiovascular DiseaseDat T Tran, Dan Palfrey, Robert Welsh
Pharmacoeconomics - Open|August 21, 2019
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature ReviewPeter Wigfield, Urbano Sbarigia, Mahmoud Hashim, et al.
Pharmacoeconomics - Open|May 31, 2025
Adjusting Health State Utility Values for Multiple Conditions: Real-World EQ-5D-3L Data Modeling in BrazilMilene Rangel da Costa, Bráulio Dos Santos Júnior, Marisa da Silva Santos
Pharmacoeconomics - Open|February 11, 2026
Understanding the Humanistic Burden of Metabolic Dysfunction-Associated Steatohepatitis Liver Disease in the US Population: Age/Sex Stratified Analysis of Morbidity and MortalityAndrew H Briggs, Ziyi Lin, Daniel Aggio, et al.
Pharmacoeconomics - Open|January 27, 2026
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost NeutralityArendse Tange Larsen, Liza Sopina, Eske Kvanner Aasvang, et al.
Pharmacoeconomics - Open|January 29, 2026
Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic EvaluationsAlyssa Grant, Dima Kabbani, Andrew Vuong, et al.
Pharmacoeconomics - Open|March 20, 2025
Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims DatabasePavo Marijic, Roman Kliemt, Martin Krammer, et al.
Pharmacoeconomics - Open|February 11, 2018
Out-of-Pocket Household Expenditures on Medical Injections in CambodiaSachiko Ozawa, Tatenda T Yemeke, Alie F Tawah, et al.
Pharmacoeconomics - Open|January 9, 2019
The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay MethodNajme Moradi, Arash Rashidian, Shirin Nosratnejad, et al.
Pharmacoeconomics - Open|February 12, 2019
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Rui Duarte, et al.
Pageof 61